



2-20-2014

Nuclear Receptor 4a3 (Nr4a3) Regulates Murine Mast Cell Responses and Granule Content

Gianni Garcia-Faroldi

Swedish University of Agricultural Sciences, Sweden

Fabio R. Melo

Swedish University of Agricultural Sciences, Sweden

Dennis Bruemmer

University of Kentucky, dennis.bruemmer@uky.edu

Orla M Conneely

Baylor College of Medicine

Gunnar Pejler

Swedish University of Agricultural Sciences, Sweden

See next page for additional authors

[Click here to let us know how access to this document benefits you.](#)

Follow this and additional works at: https://uknowledge.uky.edu/internalmedicine_facpub

 Part of the [Medicine and Health Sciences Commons](#)

Repository Citation

Garcia-Faroldi, Gianni; Melo, Fabio R.; Bruemmer, Dennis; Conneely, Orla M; Pejler, Gunnar; and Lundequist, Anders, "Nuclear Receptor 4a3 (Nr4a3) Regulates Murine Mast Cell Responses and Granule Content" (2014). *Internal Medicine Faculty Publications*. 34.

https://uknowledge.uky.edu/internalmedicine_facpub/34

Authors

Gianni Garcia-Faroldi, Fabio R. Melo, Dennis Bruemmer, Orla M Conneely, Gunnar Pejler, and Anders Lundequist

Nuclear Receptor 4a3 (Nr4a3) Regulates Murine Mast Cell Responses and Granule Content**Notes/Citation Information**

Published in *PLoS ONE*, v. 9, issue 2, no. e89311.

© 2014 Garcia-Faroldi et al.

This is an open-access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Digital Object Identifier (DOI)

<http://dx.doi.org/10.1371/journal.pone.0089311>

Nuclear Receptor 4a3 (Nr4a3) Regulates Murine Mast Cell Responses and Granule Content

Gianni Garcia-Faroldi¹, Fabio R. Melo¹, Dennis Bruemmer², Orla M. Conneely³, Gunnar Pejler¹, Anders Lundequist^{1*}

1 Swedish University of Agricultural Sciences, Department of Anatomy, Physiology and Biochemistry, BMC, Uppsala, Sweden, **2** Saha Cardiovascular Research Center, University of Kentucky College of Medicine, Wethington, Kentucky, United States of America, **3** Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas, United States of America

Abstract

Nuclear receptor 4a3 (Nr4a3) is a transcription factor implicated in various settings such as vascular biology and inflammation. We have recently shown that mast cells dramatically upregulate *Nuclear receptor 4a3* upon activation, and here we investigated the functional impact of Nuclear receptor 4a3 on mast cell responses. We show that Nuclear receptor 4a3 is involved in the regulation of cytokine/chemokine secretion in mast cells following activation via the high affinity IgE receptor. Moreover, Nuclear receptor 4a3 negatively affects the transcript and protein levels of mast cell tryptase as well as the mast cell's responsiveness to allergen. Together, these findings identify Nuclear receptor 4a3 as a novel regulator of mast cell function.

Citation: Garcia-Faroldi G, Melo FR, Bruemmer D, Conneely OM, Pejler G, et al. (2014) Nuclear Receptor 4a3 (Nr4a3) Regulates Murine Mast Cell Responses and Granule Content. PLoS ONE 9(2): e89311. doi:10.1371/journal.pone.0089311

Editor: Sven G. Meuth, University of Muenster, Germany

Received: May 14, 2013; **Accepted:** January 22, 2014; **Published:** February 20, 2014

Copyright: © 2014 Garcia-Faroldi et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by grants from: Magnus Bergvall Foundation, The Swedish Cancer Foundation, The Swedish Research Council, Formas, King Gustaf V's 80-year Anniversary Fund, and Fundación Española para la Ciencia y la Tecnología y Ministerio de Educación, Cultura y Deporte. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: Anders.Lundequist@slu.se

Introduction

Mast cells are important components of the innate and adaptive immune system, most notably taking part in the defense against parasites, bacteria and viruses [1,2]. However, there are also several detrimental effects associated with mast cells, e.g. allergy and rheumatoid arthritis [1,2]. The mast cell expresses the high affinity IgE-receptor, FcεRI. FcεRI crosslinking, e.g. by an allergen, results in the immediate release of preformed mediators that are stored in secretory granules [3] and also to the activation of transcriptional events, e.g. mediated by NFAT, NFκB and AP-1, leading to cytokine generation and release. Mast cells are broadly divided into mucosal and connective tissue types based on their repertoire of expressed proteases, for instance chymase, tryptase and carboxypeptidase A3 (CPA3) type, though how the expression of these proteases is regulated is poorly understood [1,2,4]. Transcriptional regulation involving GATA-1, FOG and MITF is also an essential part of the development of the mast cell into its different subtypes [5,6], and mast cell development and phenotype is additionally influenced by the cytokine and growth factor milieu in the respective tissues [7,8].

The nuclear receptor subfamily 4a (Nr4a) encompasses three members, *Nur77/Nr4a1*, *Nurr1/Nr4a2* and *NOR-1/Nr4a3*, which are early response genes reacting to a variety of stimuli such as cytokines, infectious agents, growth factors and cellular stress [9–13]. The activities of the Nr4a3 family members are ligand-independent, meaning that once translated they do not require further stimuli to exert their function. However, their activity is

influenced by cellular location, which might be regulated by phosphorylation [14]. Members of the Nr4a family partake in many cellular responses, including those affecting the immune system and inflammation as shown by the contribution of Nr4a1 and Nr4a3 to induction of T-cell and macrophage apoptosis [14–16]. Moreover, cytokine and chemokine responses are regulated by Nr4a family members in both macrophages and T-cells, lending additional support of their role in immunomodulation [17,18].

In a previous study where the global impact of bacterial infection on mast cell responses was studied, it was noted that exposure of mast cells to gram-positive Streptococci resulted in a dramatic upregulation of all three Nr4a members, with the most striking increase noted for Nr4a3 [19]. In a subsequent study we showed that Nr4a members, in particular Nr4a3, were strongly induced also by mast cell activation through FcεRI crosslinking [20]. Prompted by these findings, we here investigated the functional impact of Nr4a3 on mast cells. We show that Nr4a3 is required for optimal cytokine generation following antigen-induced mast cell activation. Moreover, we show that the presence of Nr4a3 regulates FcεRI-mediated degranulation, and finally we show that Nr4a3 selectively suppresses the transcript and the resulting protein of the tryptase mouse mast cell protease 6 (mMCP-6; encoded by *Tpsb2*). Together, these findings suggest a hitherto unrecognized role of Nr4a3 in regulating mast cell homeostasis and activation.

Table 1. Primers used for qPCR.

Target	Sequence
mouse	
<i>Hprt</i> , fw ^a	5'-GAT TAG CGA TGA TGA ACC AGG TTA-3'
<i>Hprt</i> , rev ^b	5'-GAC ATC TCG AGC AAG TCT TTC AGT C-3'
<i>Srgn</i> , fw	5'-GCA AGG TTA TCC TGC TCG GAG-3'
<i>Srgn</i> , rev	5'-GGT CAA ACT GTG GTC CCT TCT C-3'
<i>Tpsb2</i> , fw	5'-CAT TGA TAA TGA CGA GCC TCT CC-3'
<i>Tpsb2</i> , rev	5'-CAT CTC CCG TGT AGA GGC CAG-3'
<i>Mcpt4</i> , fw	5'-GAA GCT TCA AAA GAA-3'
<i>Mcpt4</i> , rev	5'-GGT TCT GTC ACT CCA-3'
<i>Cpa3</i> , fw	5'-TGA CAG GGA GAA GGT ATT CCG-3'
<i>Cpa3</i> , rev	5'-CCA AGG TTG ACT GGA TGG TCT-3'

All primers were designed using the software *Primer Express* Version 1.0.

^afw, forward primer,

^brev, reverse primer.

doi:10.1371/journal.pone.0089311.t001

Materials and Methods

This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The institutional animal care and use committee at the University of Kentucky approved all procedures on mice. The animals were maintained and treated according to the guidelines set by IACUC. Euthanasia was carried out using CO₂ according to AVMA Guidelines for the Euthanasia of Animals.

Reagents

Polyclonal antibodies against mMCP-6 (encoded by *Tpsb2*), and CPA3 were raised in rabbits [22]. Antibodies from Cell Signaling were purchased to identify NFAT1 (5861), Fyn (4023), Lyn (2796), IKK β (2370) and IKK α (2682). Rabbit polyclonal antibody towards β -actin (sc-130656) was from Santa Cruz. ELISA kits were from eBioscience (MCP-1, IL-6, IL-13) and Peprtech (TNF α), respectively.

Cell Culture

Bone-marrow cells from C57BL/6 mice were obtained from femoral and tibial bone of wild type (WT) and Nr4a3^{-/-} [21] mice and cultured in DMEM, supplemented with 10% heat-inactivated fetal bovine serum, 60 μ g/ml Penicillin, 50 μ g/ml Streptomycinsulfate, 2 mM l-glutamine and 10 ng/ml recombinant IL-3 (Peprtech). The cells were kept at a concentration of 0.5–1 \times 10⁶ cells/ml with weekly changes of medium [22].

Mast Cell Activation

For IgE-induced activation, cells were sensitized with anti-TNP IgE at 1 μ g/ml overnight, washed, resuspended in new media and stimulated with TNP-OVA (0.4 μ g/ml or indicated concentrations) [22]. Cells were collected at various time points by centrifugation; media and cell fractions were frozen and stored at -20°C. The effect on TNF α , MCP-1, IL-6 and IL-13 release was determined in cell supernatants using ELISA as detailed by the manufacturer.

β -Hexosaminidase Activity

β -Hexosaminidase activity was measured in solubilized cell pellets and supernatants from resting or activated cells as described [22].

Cell Lysate

Lysate buffer (200 ml PBS, 2 M NaCl, 0.5% Triton X-100) was added to cell pellets (1 \times 10⁶ cells/pellet) followed by vortexing. The protein concentration in the lysates was determined with the Bradford method using BSA as a standard. The determined protein concentration was used for normalizing the enzyme activity and Western blot protein loading. Samples used for Western Blot analysis were treated with protease and phosphatase inhibitors.

Enzymatic Activity

Duplicate samples of cell lysate (20 ml) were mixed with 80 ml H₂O to which 20 ml of a 2 mM solution (in H₂O) of the chromogenic substrate S-2288 (H-D-Isoleucyl-L-prolyl-L-arginine-p-nitroaniline dihydrochloride; Chromogenix) was added. Changes in absorbance were recorded at 405 nm and used to calculate initial reaction velocities.




Figure 1. Nr4a3 does not affect mast cell development. (A, B) Toluidine blue staining of WT (A) and Nr4a3^{-/-} (B) mast cells after 4 weeks of culture. Note that the absence of Nr4a3 does not affect the morphology or granular staining of the cells.

doi:10.1371/journal.pone.0089311.g001




Figure 2. Nr4a3 affects cytokine/chemokine secretion in response to Fc ϵ R1 cross-linking. (A–D) WT and Nr4a3^{-/-} mast cells were incubated with TNP-specific IgE over-night followed by activation for 4 hours or 24 hours with TNP-OVA as indicated. Supernatants were analyzed for levels of MCP-1 (A), TNF α (B), IL-6 (C) and IL-13 (D) by ELISA (T-test, n = 4; *p \leq 0.05). The lack of Nr4a3 is associated with a reduction in cytokine release following Fc ϵ R1 cross-linking.

doi:10.1371/journal.pone.0089311.g002

Induction of Cell Death

Triplicates of 1 ml BMDCs (0.5×10^6 cells/ml) were transferred into individual wells of a 24-well flat-bottomed plate, and were either left untreated or treated with cytotoxic agents: L-Leucyl-L-Leucine methyl ester (LLME, 200 mM), Cycloheximide (CHX, 5 μ g/ml) or H₂O₂ (0.75 mM) in complete culture medium, followed by incubation for different time periods (as specified in the figure legends). Triplicates of 100 μ l of cell suspension were transferred into a 96-well plate and cell viability was measured using CellTiter-Blue reagent (Promega-Invitrogen, Carlsbad, CA). The plate was read using a microplate reader (Infinite M200–TECAN) at 560 nm (excitation) and 590 nm (emission).

Western Blot

Cell lysates were mixed with 4 \times reducing SDS-PAGE sample buffer and subjected to SDS-PAGE on 12% gels. Thereafter, proteins were blotted onto PVDF membranes, followed by blocking in Odyssey Blocking Buffer diluted 1:1 in TBS for 1 h. Next, the membranes were incubated with primary antibodies (diluted 1:500 for mMCP6, diluted 1:1000 for all others) in Odyssey Blocking Buffer:TBS (1:1), overnight at 4 $^{\circ}$ C. After

washing with TBS/0.1% Tween-20, the membranes were incubated with appropriate secondary antibodies conjugated to IRDye 800 or IRDye 680 (diluted 1:1000 in Odyssey Blocking Buffer:TBS) for 1 h at room temperature. The membranes were subsequently washed twice in TBS/0.1% Tween-20 and once in TBS before detecting the signal using an Odyssey Infrared Imaging System (Li-Cor Biosciences, 9201-01).

Quantitative Real Time RT-PCR

Total RNA preparation and quantitative real-time PCR (qPCR) were performed as previously described [23]. For primers used, see Table 1.

Statistical Analysis

Statistical analyses using two tailed, Student's t-test or ANOVA were performed using GraphPad Prism 4. Differences were considered significant if the p-values were 0.05 or less. All experiments were repeated at least three times; representative experiments are displayed.




Figure 3. Nr4a3 modulates signaling pathways involved in mast cell degranulation (A–F). (A–B) Whole cell lysates from resting WT and Nr4a3^{-/-} mast cells were prepared and analyzed by Western blot for the Src-kinases Fyn (A) and Lyn (B). The signal was compared against β-actin followed by normalization using the average signal from WT samples set to 1. (C–D) Graphical representation of the densitometric analysis for Fyn (C) and Lyn (D) (T-test, n = 4; *p ≤ 0.05). (E) WT and Nr4a3^{-/-} mast cells were incubated with TNP-specific IgE over-night followed by activation for 30 minutes with increasing amounts of TNP-OVA. Supernatants were collected and were analyzed for β-hexosaminidase activity as a measure of the extent of degranulation. (ANOVA, n = 4; *p ≤ 0.05). (F) Whole cell lysates were prepared and analyzed for their β-hexosaminidase content. doi:10.1371/journal.pone.0089311.g003

Results and Discussion

Nr4a3 is Required for Optimal FcεRI-induced Cytokine/Chemokine Generation in Mast Cells

To study the influence of Nr4a3 on mast cell function we cultured bone-marrow cells isolated from WT and Nr4a3-deficient mice in the presence of IL-3, which results in maturation of precursor cells into mast cells, i.e. bone marrow-derived mast cells (BMMCs). Toluidine blue staining of four-week old cultures showed no apparent morphological differences between WT and

Nr4a3-deficient mast cells (Fig. 1A–B), suggesting that Nr4a3 does not affect mast cell development.

In a previous study we found that the *Nr4a3* transcript was potently upregulated following FcεRI crosslinking, suggesting that Nr4a3 might participate in the regulation of this pathway [20]. The events triggered by FcεRI crosslinking include cytokine/chemokine induction as well as degranulation whereby the contents of the mast cell secretory granules (e.g. β-hexosaminidase, proteases and biogenic amines) are released. To explore the potential role of Nr4a3 in regulating these processes we first studied the effect of Nr4a3-deficiency on the secretion of IL-6, IL-




Figure 4. (A–C) Nr4a3-deficient mast cells are more susceptible than WT cells to cell death induced by granule disruption. WT and Nr4a3^{-/-} mast cells were treated with 200 mM LLME (A), 5 μg/ml Cycloheximide (B) or 0.75 mM H₂O₂ (C). The viability was determined at the indicated time-points using CellTiter-Blue reagent (ANOVA, N = 6, *p ≤ 0.05).

doi:10.1371/journal.pone.0089311.g004

13, MCP-1 and TNFα, based on the known importance of these cytokines/chemokines in mast cell responses [1]. As seen in Fig. 2A–D, the absence of Nr4a3 led to a significant reduction in the secretion of the investigated cytokines and chemokines in

response to FcεRI crosslinking, thus indicating that Nr4a3 promotes the induction of these factors. In turn, this suggests that Nr4a3 may have a pro-inflammatory role in terms of regulating cytokine/chemokine responses in a mast cell setting. The findings are in line with previous studies in which Nr4a family members have been implicated in the regulation of inflammatory gene expression in macrophages activated through pattern recognition receptors [18].

The canonical NFκB-pathway has been implicated in antigen-induced generation of various cytokines in mast cells [24]. It has been shown that Nr4a-members influence NFκB-signaling by modulating the expression of components of the Inhibitor of nuclear factor-κB-kinase (IKK) complex in macrophages [18]. In mast cells, IKKα and IKKβ have been shown to be important for cytokine generation following antigen activation [24,25]. Nr4a3-mediated effects on the expression of IKKα and IKKβ could therefore potentially explain the reduced cytokine response in mast cells devoid of Nr4a3. We thus measured the levels of IKKα and IKKβ in mast cells but found that neither the IKKα nor the IKKβ levels were significantly altered due to Nr4a3 deficiency (data not shown). The major pathway for FcεRI-induced IL-13, MCP-1 and TNFα generation in mast cells involves transcription factors belonging to the Nuclear Factor of Activated T cells (NFAT) family [20,26]. We therefore explored the possibility that the lack of Nr4a3 influenced the protein levels of NFAT1 in mast cells, but could not detect any significant change (data not shown).

The earliest event following FcεRI crosslinking is activation of the Src-family kinases Lyn and Fyn, which phosphorylate the immunoreceptor tyrosine-based activation motifs of the β and γ subunits of FcεRI [27,28]. Both Lyn and Fyn are positive regulators of the downstream signaling cascade leading to degranulation and cytokine generation. When determining the total levels of Fyn and Lyn we found that Nr4a3 deficiency was associated with reduced Fyn expression whereas Lyn was unaffected (Fig. 3A–D). In mast cells, Lyn and Fyn both propagate the signal via Syk but Fyn also utilizes pathways involving phosphatidylinositol 3-kinase (PI3K) or Stat5 [29,30]. Future investigations will determine which signaling pathway is affected by the Nr4a3 dependent reduction in Fyn levels. Nevertheless, the reduction in Fyn levels could be one explanation for the reduced cytokine generation in Nr4a3 deficient mast cells, but a direct effect of Nr4a3 on cytokine transcription cannot be ruled out.

To further assess whether Nr4a3 influences the degree of FcεRI-induced activation, we determined whether the actual extent of degranulation in response to FcεRI crosslinking was affected by the absence of Nr4a3. To this end we measured the release of β-hexosaminidase. Interestingly, in dose-response experiments with increasing concentrations of antigen, Nr4a3^{-/-} mast cells exhibited an increased reactivity to antigen as illustrated by the augmented release of β-hexosaminidase from activated Nr4a3-deficient mast cells compared to their WT counterparts (Fig. 3E). A possible explanation for this finding would be that Nr4a3 affects the production and storage of β-hexosaminidase. However, total β-hexosaminidase activity determinations showed that WT and Nr4a3^{-/-} mast cells were indistinguishable (Fig. 3F). Taken together, these findings thus indicate that Nr4a3 influences processes leading to degranulation.

Previous studies have implicated Nr4a family members, in particular Nr4a1 and Nr4a3, in apoptosis [14–16]. It was therefore of interest to investigate whether the absence of Nr4a3 affects apoptosis in a mast cell context. To address this, mast cells were subjected to the pro-apoptotic agents cycloheximide, H₂O₂ or L-Leucyl-L-Leucine methyl ester (LLME) followed by measurements of viability [31–33]. Interestingly, we found that Nr4a3-deficient




Figure 5. Nr4a3 regulates the transcription of mast cell granule components. Total RNA was extracted from WT and Nr4a3^{-/-} mast cells followed by qPCR analysis for levels of mRNA encoded by *Srgn* (A), *Mcpt4* (B), *Tpsb2* (C) and *Cpa3* (D). *Hprt* was used as house-keeping gene; transcript data were calculated according to DDCT relative to the expression in WT cells (T-test, n=4; *p≤0.05). doi:10.1371/journal.pone.0089311.g005

mast cells were more susceptible to LLME-induced cell death than were WT cells, whereas no difference in sensitivity to cycloheximide and H₂O₂ was seen when comparing WT and Nr4a3^{-/-} mast cells (Fig. 4A–C). We have recently shown that tryptase, and other serglycin-dependent proteases, induce cell death when released into the cytosol following exposure to the lysosomotropic compound LLME [32,34]. Changes in protease levels due to the lack of Nr4a3 could hence explain the difference in susceptibility to LLME-induced cell death.

Nr4a3 Regulates the Transcription of Serglycin and the Tryptase *Tpsb2*

A characteristic feature of mast cells is their secretory granules containing vast amounts of histamine alongside mast cell-specific proteases, the latter requiring serglycin proteoglycan to be stored [35,36]. To investigate if Nr4a3 influences mast cell function by regulating the mast cell-specific proteases and serglycin proteoglycan, we performed qPCR determinations of transcripts for serglycin (*Srgn*), chymase (*Mcpt4*), tryptase (*Tpsb2*; encoding mMCP-6) and CPA3 (*Cpa3*) in WT and Nr4a3^{-/-} mast cells (Fig. 5A–D) using the primers specified in Table 1. We found that Nr4a3 deficiency led to an ~2-fold increase in *Tpsb2* transcript levels and to a minor, but significant, reduction of *Srgn* transcript, whereas the expression of *Mcpt4* and *Cpa3* were unaffected.

To elucidate if the effects on transcription translate into a change in protein levels we performed Western blot analysis on cell lysates from WT and Nr4a3^{-/-} mast cells (Fig. 6 A–B). In accordance with the mRNA expression analysis, the levels of mMCP-6 protein were significantly higher in Nr4a3^{-/-} mast cells than in WT counterparts. Moreover, the increase in mMCP-6 mRNA and protein was accompanied by a corresponding

increase in the levels of trypsin-like enzymatic activity, as judged by the rate of turn-over of a chromogenic substrate for trypsin-like proteases such as mMCP-6 (Fig. 6 C). Considering that tryptase is one of the most abundant proteins in mast cells [4,37], the approximately 2-fold increase in transcript and activity represents a quite substantial change. Based on the notion that mast cell proteases promote cell death, it is plausible that the increased susceptibility of Nr4a3-deficient mast cells to LLME-induced cell death is due to their augmented levels of tryptase.

The expression of the mMCP-6 gene (*Tpsb2*) is governed by MITF, PEBP2/CBF and c-jun, which independently or synergistically regulate *Tpsb2* transcription [38–40]. Based on our results it is thus plausible that Nr4a3 either acts as a repressor by directly binding to the *Tpsb2* promoter region, or indirectly by negatively influencing the levels of MITF, PEBP2/CBF and/or c-jun. Tryptase is viewed as an important molecule in a number of inflammatory conditions where its presence either is beneficial [41] or detrimental [42,43]. Thus, the suppressive influence of Nr4a3 on *Tpsb2* transcription may have important consequences for the outcome of inflammatory settings in which tryptase participates.

The present study identifies a novel role for Nr4a3 in regulating mast cell responses, which is summarized in Fig. S1. Intriguingly, our data suggest that although Nr4a3 promotes the secretion of pro-inflammatory cytokines and chemokines, it exerts a negative influence on pathways leading to degranulation responses and the expression of one of the major granule compounds (mMCP-6). Taken together, the differential influence Nr4a3 has on cytokine generation and tryptase levels suggests that Nr4a3 is involved in several regulatory pathways important for mast cell function. It is thus conceivable that Nr4a3 has a role in regulating the balance between different arms of responses induced by mast cell




Figure 6. Nr4a3 suppresses the levels of trypsin protein and enzymatic activity. (A) Whole cell lysates from WT and Nr4a3^{-/-} mast cells were prepared and analyzed by Western blot for mMCP-6 and CPA3 as indicated (the upper and lower panels represent individual analyses, performed on the same membrane that was stripped of protein between analyses). The absence of Nr4a3 results in increased levels of mMCP-6 but does not affect CPA3. (B) Quantification of band intensities for mMCP-6 showing a significant increase in mMCP-6 protein in the absence of Nr4a3. (n = 4; *p ≤ 0.05). The level of mMCP-6 and CPA3 proteins were quantified and compared against b-actin followed by normalization using the average signal from WT samples set to 1. (C) Whole cell lysates from WT and Nr4a3^{-/-} mast cells were prepared and analyzed for trypsin-like activity using the chromogenic substrate S-2288. Note that the absence of Nr4a3 results in increased trypsin-like enzymatic activity. (T-test, n = 4; *p ≤ 0.05). doi:10.1371/journal.pone.0089311.g006

activation, by promoting degranulation-independent events (cytokine/chemokine secretion) in favor of degranulation and expression of certain granule-localized proteases. It is important to stress that mast cell degranulation, although essentially regarded as a

pro-inflammatory event, also has important regulatory consequences through the proteolytic inactivation of pro-inflammatory cytokines by proteases released by degranulation [44–47]. The present study has focused on how Nr4a3 influences the antigen-

induced responses in mast cells and thus its implications for allergies. Based on the findings in the present investigation it is plausible that interfering with Nr4a3 function may augment immediate hypersensitivity reactions as a result of increased mast cell degranulation, whereby mediators such as histamine are released. However, to fully comprehend the influence of Nr4a3 on mast cell function in allergic reactions, additional research in animal models of allergy is warranted.

Supporting Information

Figure S1 Summary of the findings presented in this article. In resting mast cells, Nr4a3 augments transcription of *Fyn*

References

- Galli SJ, Grimbaldston M, Tsai M (2008) Immunomodulatory mast cells: negative, as well as positive, regulators of immunity. *Nat Rev Immunol* 8: 478–486.
- Metcalf DD, Baram D, Mekori YA (1997) Mast cells. *Physiol Rev* 77: 1033–1079.
- Lundequist A, Pejler G (n.d.) Biological implications of preformed mast cell mediators. *Cell Mol Life Sci* 68: 965–975.
- Pejler G, Rönnberg E, Waern I, Wernersson S (2010) Mast cell proteases: multifaceted regulators of inflammatory disease. *Blood* 115: 4981–4990.
- Murakami M, Iwata Y, Funaba M (2007) Expression and transcriptional activity of alternative splice variants of *Mitf* exon 6. *Mol Cell Biochem* 303: 251–257.
- Arinobu Y, Iwasaki H, Akashi K (2009) Origin of basophils and mast cells. *Allergol Int* 58: 21–28. <http://pubmed/19153533>. Accessed 2012 Dec 10.
- Kitamura Y (2003) Heterogeneity of Mast Cells and Phenotypic Change Between Subpopulations. *Annu Rev Immunol* 7: 59–76. Available: <http://dx.doi.org/10.1146/annurev.iy.07.040189.000423>.
- Galli SJ, Borregaard N, Wynn TA (2011) Phenotypic and functional plasticity of cells of innate immunity: macrophages, mast cells and neutrophils. *Nat Immunol* 12: 1035–1044.
- Beaudry G, Langlois MC, Weppe I, Rouillard C, Lévesque D (2000) Contrasting patterns and cellular specificity of transcriptional regulation of the nuclear receptor nerve growth factor-inducible B by haloperidol and clozapine in the rat forebrain. *J Neurochem* 75: 1694–1702.
- Glass CK, Saijo K (2010) Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells. *Nat Rev Immunol* 10: 365–376.
- Maheux J, Ethier I, Rouillard C, Lévesque D (2005) Induction patterns of transcription factors of the *nur* family (*nurr1*, *nur77*, and *nor-1*) by typical and atypical antipsychotics in the mouse brain: implication for their mechanism of action. *J Pharmacol Exp Ther* 313: 460–473.
- Maxwell MA, Muscat GEO (2006) The NR4A subgroup: immediate early response genes with pleiotropic physiological roles. *Nucl Recept Signal* 4: e002.
- Pols TWH, Bonta PI, de Vries CJM (2007) NR4A nuclear orphan receptors: protective in vascular disease? *Curr Opin Lipidol* 18: 515–520.
- Thompson J, Burger ML, Whang H, Winoto A (2010) Protein kinase C regulates mitochondrial targeting of Nur77 and its family member Nor-1 in thymocytes undergoing apoptosis. *Eur J Immunol* 40: 2041–2049.
- Cheng LE, Chan FK, Cado D, Winoto A (1997) Functional redundancy of the Nur77 and Nor-1 orphan steroid receptors in T-cell apoptosis. *EMBO J* 16: 1865–1875.
- Hanna RN, Carlin LM, Hubbeling HG, Nackiewicz D, Green AM, et al. (2011) The transcription factor NR4A1 (Nur77) controls bone marrow differentiation and the survival of Ly6C⁺ monocytes. *Nat Immunol* 12: 778–785.
- Bonta PI, van Tiel CM, Vos M, Pols TWH, van Thienen J V, et al. (2006) Nuclear receptors Nur77, Nurr1, and NOR-1 expressed in atherosclerotic lesion macrophages reduce lipid loading and inflammatory responses. *Arterioscler Thromb Vasc Biol* 26: 2288–2294.
- Pei L, Castrillo A, Tontonoz P (2006) Regulation of macrophage inflammatory gene expression by the orphan nuclear receptor Nur77. *Mol Endocrinol* 20: 786–794. Available: <http://www.ncbi.nlm.nih.gov/pubmed/16339277>. Accessed 2012 Nov 12.
- Rönnberg E, Guss B, Pejler G (2010) Infection of mast cells with live streptococci causes a toll-like receptor 2- and cell-cell contact-dependent cytokine and chemokine response. *Infect Immun* 78: 854–864.
- Lundequist A, Calounova G, Wensman H, Rönnberg E, Pejler G (2011) Differential regulation of Nr4a subfamily nuclear receptors following mast cell activation. *Mol Immunol* 48: 1753–1761.
- Nomiyama T, Nakamachi T, Gizard F, Heywood EB, Jones KL, et al. (2006) The NR4A orphan nuclear receptor NOR1 is induced by platelet-derived growth factor and mediates vascular smooth muscle cell proliferation. *J Biol Chem* 281: 33467–33476.
- Rönnberg E, Pejler G (2012) Serglycin: the master of the mast cell. *Methods Mol Biol* 836: 201–217.
- Duelli A, Ronnberg E, Waern I, Ringvall M, Kolset SO, et al. (2009) Mast Cell Differentiation and Activation Is Closely Linked to Expression of Genes Coding for the Serglycin Proteoglycan Core Protein and a Distinct Set of Chondroitin Sulfate and Heparin Sulfotransferases. *J Immunol* 183: 7073–7083.
- Peng Y, Power MR, Li B, Lin T-J (2005) Inhibition of IKK down-regulates antigen+IgE-induced TNF production by mast cells: a role for the IKK-IkappaB-NF-kappaB pathway in IgE-dependent mast cell activation. *J Leukoc Biol* 77: 975–983.
- Nakagomi D, Suzuki K, Nakajima H (2012) Critical roles of IκB kinase subunits in mast cell degranulation. *Int Arch Allergy Immunol* 158 Suppl : 92–95. Available:
- Klein M, Klein-Hessling S, Palmethofer A, Serfling E, Tertilt C, et al. (2006) Specific and redundant roles for NFAT transcription factors in the expression of mast cell-derived cytokines. *J Immunol* 177: 6667–6674.
- Hernandez-Hansen V, Smith AJ, Surviladze Z, Chigacov A, Mazel T, et al. (2004) Dysregulated FcεRI signaling and altered Fyn and SHIP activities in Lyn-deficient mast cells. *J Immunol* 173: 100–112.
- Parravicini V, Gadina M, Kovarova M, Odom S, Gonzalez-Espinosa C, et al. (2002) Fyn kinase initiates complementary signals required for IgE-dependent mast cell degranulation. *Nat Immunol* 3: 741–748.
- Tshori S, Razin E (2010) Editorial: Mast cell degranulation and calcium entry—the Fyn-calcium store connection. *J Leukoc Biol* 88: 837–838.
- Pullen NA, Falanga YT, Morales JK, Ryan JJ (2012) The Fyn-STAT5 Pathway: A New Frontier in IgE- and IgG-Mediated Mast Cell Signaling. *Front Immunol* 3: 117.
- Martin SJ, Lennon S V, Bonham AM, Cotter TG (1990) Induction of apoptosis (programmed cell death) in human leukemic HL-60 cells by inhibition of RNA or protein synthesis. *J Immunol* 145: 1859–1867.
- Melo FR, Lundequist A, Calounova G, Wernersson S, Pejler G (2011) Lysosomal membrane permeabilization induces cell death in human mast cells. *Scand J Immunol* 74: 354–362.
- Cerella C, Coppola S, Maresca V, De Nicola M, Radogna F, et al. (2009) Multiple mechanisms for hydrogen peroxide-induced apoptosis. *Ann N Y Acad Sci* 1171: 559–563.
- Melo FR, Waern I, Rönnberg E, Åbrink M, Lee DM, et al. (2011) A role for serglycin proteoglycan in mast cell apoptosis induced by a secretory granule-mediated pathway. *J Biol Chem* 286: 5423–5433.
- Kolset SO, Pejler G (2011) Serglycin: a structural and functional chameleon with wide impact on immune cells. *J Immunol* 187: 4927–4933.
- Hallgren J, Pejler G (2006) Biology of mast cell tryptase. An inflammatory mediator. *FEBS J* 273: 1871–1895. Available:
- Lundequist A, Pejler G (2011) Biological implications of preformed mast cell mediators. *Cell Mol Life Sci* 68: 965–975.
- Morii E, Tsujimura T, Jippo T, Hashimoto K, Takebayashi K, et al. (1996) Regulation of mouse mast cell protease 6 gene expression by transcription factor encoded by the *mi* locus. *Blood* 88: 2488–2494.
- Ogihara H, Kanno T, Morii E, Kim DK, Lee YM, et al. (1999) Synergy of PEBP2/CBF with *mi* transcription factor (MITF) for transactivation of mouse mast cell protease 6 gene. *Oncogene* 18: 4632–4639.
- Kim D-K, Lee Y-M (2004) Requirement of c-jun transcription factor on the mouse mast cell protease-6 expression in the mast cells. *Arch Biochem Biophys* 431: 71–78.
- Thakurdas SM, Melicoff E, Sansores-Garcia L, Moreira DC, Petrova Y, et al. (2007) The mast cell-restricted tryptase mMCP-6 has a critical immunoprotective role in bacterial infections. *J Biol Chem* 282: 20809–20815.
- Hamilton MJ, Sinnamon MJ, Lyng GD, Glickman JN, Wang X, et al. (2011) Essential role for mast cell tryptase in acute experimental colitis. *Proc Natl Acad Sci U S A* 108: 290–295.
- Shin K, Nigrovic PA, Crish J, Boilard E, McNeil HP, et al. (2009) Mast cells contribute to autoimmune inflammatory arthritis via their tryptase/heparin complexes. *J Immunol* 182: 647–656.
- Waern I, Karlsson I, Thorpe M, Schlenner SM, Feyerabend TB, et al. (2012) Mast cells limit extracellular levels of IL-13 via a serglycin proteoglycan-serine protease axis. *Biol Chem* 393: 1555–1567.

45. Waern I, Lundequist A, Pejler G, Wernersson S (2012) Mast cell chymase modulates IL-33 levels and controls allergic sensitization in dust-mite induced airway inflammation. *Mucosal Immunol*.
46. Piliponsky AM, Chen C-C, Grimbaldston MA, Burns-Guydish SM, Hardy J, et al. (2010) Mast cell-derived TNF can exacerbate mortality during severe bacterial infections in C57BL/6-KitW-sh/W-sh mice. *Am J Pathol* 176: 926–938.
47. Zhao W, Oskeritzian CA, Pozez AL, Schwartz LB (2005) Cytokine production by skin-derived mast cells: endogenous proteases are responsible for degradation of cytokines. *J Immunol* 175: 2635–2642.